Agenus | AGEN - Debt


Agenus reported $35.54M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Celldex Therapeutics USD 1.91M 428K Mar/2026
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Intrexon USD 0 13.82M Jun/2024
J&J USD 49.04B 5.95B Jun/2026
Jiangsu Hengrui CNY 67.47M 6.76M Mar/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck EUR 12.04B 86M Mar/2026
Merck USD 49.12B 222M Mar/2026
Northwest Biotherapeutics USD 32.94M 6.93M Sep/2023
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.19B 536M Jun/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 39.33M 321K Mar/2026